Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 20/20 | 0.73 |
| ▸ | CDK8 | P49336 | 20/20 | 0.73 |
| ▸ | CDK19 | Q9BWU1 | 20/20 | 0.73 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.44 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038809 | 0.91 | CCNC (0.61) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7041310 | 0.90 | CCNC (0.72) | CCNCCDK8CDK19CDK9MAP3K19 | |
| Hydrochloric Acid SCHEMBL7094343 | 0.88 | CCNC (0.57) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7036281 | 0.87 | CCNC (0.59) | CCNCCDK8CDK19 | |
| SCHEMBL15104953 | 0.86 | CCNC (0.73) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL15104799 | 0.86 | CCNC (0.68) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7036696 | 0.86 | CCNC (0.69) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7242836 | 0.85 | CCNC (0.68) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7246810 | 0.85 | CCNC (0.77) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7246947 | 0.85 | CCNC (0.68) | CCNCCDK8CDK19CDK9MAP3K19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | claimed |
| EP-2617726-A1 | DIABETES THERAPEUTIC AGENT | Takeda Pharmaceutical Company Limited (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20130184272-A1 | DIABETES THERAPEUTIC AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20030185878-A1 | Process for producing phospholipid-containing drug | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1293197-A1 | PROCESS FOR PRODUCING PHOSPHOLIPID-CONTAINING DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185878-A1 | Process for producing phospholipid-containing drug | PHOSPHO1, PLTP, PTDSS2 | CCNC 3385/4885CDK8 2673/4885CDK19 3344/4885 |
| US-20130184272-A1 | DIABETES THERAPEUTIC AGENT | FABP4, GPR119, CPT1B | CCNC 3196/4885CDK8 4502/4885CDK19 4521/4885 |
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TST, STS, AHR | CCNC 2012/4885CDK8 3614/4885CDK19 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.